scPharmaceuticals secures $125M non-dilutive financing from Perceptive Advisors for debt repayment and FUROSCIX commercialization.

scPharmaceuticals Inc. announces an underwritten public offering of common stock or pre-funded warrants, with option for underwriters to buy 15% more within 30 days. The company also secures up to $125M non-dilutive financing from Perceptive Advisors, a life-sciences investor. Proceeds from both transactions will be used for debt repayment and ongoing commercialization of FUROSCIX.

August 12, 2024
4 Articles

Further Reading